Language Selector

    Innovative Medicines Initiative (IMI 2) Future Topics

    Published on 07 April 2015
    Author: Cornelia Spycher, NCP Health, Demographic Change and Wellbeing

    Consult the preliminary list of upcoming IMI 2 topics.

    Innovative Medicines Innitiative 2 (IMI 2) has published topics that are under consideration for inclusion in future IMI 2 Calls:

    • Patient perspective elicitation on benefits and risks of medicinal products, supplementing benefit risk assessments by regulators and HTAs (health technology assessments) from development through the entire life cycle
    • Development of a quantitative system toxicology (QST) platform
    • Diabetic kidney disease (DKD) biomarker idea
    • Inflammation and Alzheimer’s disease (AD): modulating microglia function – focussing on TREM2 and CD33
    • Enabling magnetic encephalography (MEG) as a biomarker for diagnosis and disease progression in mild cognitive impairment (MCI) and Alzheimer’s disease (AD)
    • Understanding the role of amyloid biomarkers in diagnosis, clinical management and treatment of patients with cognitive impairment
    • Evolving models of patient engagement and access for earlier identification of Alzheimer’s disease
    • Bringing apolipoprotein E (APOE) biology to validated Alzheimer’s disease targets

    All information regarding future IMI Call topics is indicative and subject to change.

    More Information On How To Participate